SEC Form 4 · accession 0001193125-26-355502
Relay Therapeutics, Inc. · RLAY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sanjiv Patel
Officer — President and CEO · Director
Period of report
Aug 17, 2026
Accepted (ET)
Aug 18, 2026 · 4:17 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001812364
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Aug 17, 2026 | S | 48,199 | $20.33 | D | 567,699 | D | |
| Common StockF3 | holding | — | — | — | 199,548 | I | By The Patel Family Irrevocable Trust of 2019 | |
| Common StockF3 | holding | — | — | — | 687,355 | I | By The SSP Irrevocable Trust of 2020 |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on October 30, 2025.
- F2This transaction was executed in multiple trades at prices ranging from $19.56 to $20.73. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F3These shares are held in irrevocable trusts for the benefit of the reporting person's family members. An independent trustee is trustee of the trusts. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.